Media

PETACH TIKVA, Israel, April 20, 2015 /PRNewswire/ — Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA), a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has submitted an application to the European Medicines Agency for Orphan Drug Designation for its drug candidate CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

CF102 is currently in a Phase II trial in the U.S., Israel, and Europe. The study enrolls HCC patients with Child-Pugh Class B cirrhosis who failed the only FDA approved drug on the market, Nexavar (sorafenib). The patients are treated twice daily with 25 mg of CF102, which has been found to be the most efficacious dose in our earlier Phase I/II study resulting in the longest overall survival time. CF102 is a stable drug which is hardly metabolized in the liver and therefore is suitable for treatment of liver diseases. In addition, the 25 mg dose had an excellent safety profile in the Phase I/II study and showed no hepatotoxicity and even maintained liver function in patients with advanced liver disease.

Can-Fite has already been granted Orphan Drug Status for CF102 for the indication of HCC by the U.S. Food and Drug Administration. CF102 is also approved for Compassionate Use by Israel’s Ministry of Health.

If CF102 is granted Orphan Drug Designation in Europe, Can-Fite would benefit from incentives including protocol assistance, fee reductions, and market exclusivity once the medicine is on the market for up to 10 years in European Union member nations.

“As we are currently conducting our Phase II trial for CF102 in the treatment of liver cancer, we believe this is an opportune time for us to apply for Orphan Drug Designation in Europe. If our Phase II study results are favorable, then this designation would grant us the European Medicines Agency’s valuable assistance in the development of our Phase III study protocol,” stated Pnina Fishman, CEO of Can-Fite. “Upon marketing approval, receiving market exclusivity for CF102 would be significantly beneficial to Can-Fite.”

According to Global Industry Analysts, the global market for liver cancer is projected to exceed $2 billion by 2015.

VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT: CVM) today announced that Aintree University Hospital, in Liverpool, England, has become a clinical site for the Company’s global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This is the first center to join the Multikine Phase III study in the UK.

Aintree University Hospital is a large teaching hospital in Liverpool providing a range of acute and non-acute specialties. The hospital offers specialist services with a world-class reputation to a population of 1.5 million residents across the Northwest of England. The Principal Investigator for the trial site is Professor Richard Shaw. He serves as Honorary Consultant in Oral & Maxillofacial / Head and Neck Surgery at Aintree University Hospital and is a surgeon specializing in head and neck cancers at the University of Liverpool.

“Dr. Shaw is a Key Opinion Leader in head and neck cancer who has participated in numerous trials exploring better ways to treat cancer. We are honored to have his participation and expertise in our trial.” stated CEL-SCI Chief Executive Officer Geert Kersten.

About Multikine Phase III Study

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only. A total of 880 patients are expected to be enrolled, through approximately 100 clinical centers in about 25 countries.

My Friend Cayla might be the doll of the future as she can interact with your child with an infinite number of answers and responses. Cayla can also be hooked to the internet and google’s database via her app and Bluetooth and this smart doll also speaks multiple languages. Cayla can be a study buddy or just a play pal, yes Cayla can play games too, but she’ll always be your friend. Clearvision/CorporateProfile Host, Annamaria Stewart, met Cayla at the North American International Toy Fair and had the opportunity to be the first girl in the US to custom name her, but you’ll just have to keep watching to see what name she chose.

This episode is currently airing on ClearVISION, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers.

To learn more about the doll featured in this episode visit: www.myfriendcayla.com

This year at MGA Entertainment it’s all about the hair, they have some exciting new stretchy and crazy hair Lalaloopsy Dolls and they are adding to the interaction by allowing girls to customize and bring their dolls to life with the help of Build-A-Bear. MGA is the same company who brought you the popular Bratz dolls, which was the first multicultural doll line, and they are breaking the mold once again with some new latin inspired dolls Vi and Va. Clearvision/CorporateProfile Host, Annamaria Stewart, heads to the North American International Toy fair to to check out MGA.

VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT: CVM) today announced that in March it has enrolled 29 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). March marks the third consecutive month of record enrollment for CEL-SCI this year following January and February 2015. 406 patients have been enrolled in the Phase III study as of March 31, 2015.

“The accelerating pace of enrollment in our trial is very good. We expect to see continued increases in monthly patient enrollment throughout the year as new clinical centers are added and as existing centers gain more experience with Multikine,” stated CEL-SCI Chief Executive Officer Geert Kersten.

About Multikine Phase III Study

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.

WILMINGTON, Mass., March 26, 2015 /PRNewswire/ — Implant Sciences Corporation (IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today reported the shipment of approximately $500,000 in explosives trace detection systems in Latin America, most of which were sold to a major international airline in Latin America.

“Implant Sciences continues to expand its market share in the Latin American aviation security space. We believe that the combination of our superior performance and value proposition is the impetus behind this success, which could also set the stage for follow-on orders from these customers,” stated Dr. Darryl Jones, Implant Sciences’ Global Vice President of Sales and Marketing. “We are seeing a significant increase in demand for our products since our recent checkpoint certifications from the US Transportation Security Administration (TSA) and the European Civil Aviation Conference (ECAC).”

“Our QS-B220 is specifically designed to meet the needs of aviation-related applications, including passenger, baggage, and cargo screening. As the only non-radioactive ETD in the world to pass the latest testing protocols of both TSA and ECAC, the QS-B220 is becoming the ETD of choice for a larger number of purchasers in the aviation security market,” added Dr. Bill McGann, CEO of Implant Sciences.

JERUSALEM, April 1, 2015 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the first patient has been enrolled in its Glucose Clamp Study. The study will be performed at The University of Texas Health Science Center at San Antonio and University Health System’s Texas Diabetes Institute under the supervision of Professor Ralph DeFronzo.

The glucose clamp is a method for quantifying insulin absorption in order to measure a patient’s insulin sensitivity and how well a patient metabolizes glucose. The glucose clamp technique represents the gold standard for pharmacodynamic studies in diabetes drug development.

In addition to the clamp study, Oramed plans to initiate its Phase IIb oral insulin trial in the U.S. with a protocol which includes over 30 U.S. sites covering approximately 180 patients and has both efficacy and safety as its primary end-points.

“We are pleased to have initiated this study and enrolled the first patient. We are additionally excited at the prospects of starting our larger Phase IIb trial in the near term. The data from the two trials will allow for a clearer picture of our oral insulin and its pharmacological characteristics as we move forward with our development plan,” stated Oramed CEO Nadav Kidron.

Heat Biologics is a clinical-stage company focused on developing its proprietary “ImPACT”​ (Immune Pan-Antigen Cytotoxic Therapy), a fully allogeneic (“off-the-shelf”) cell-based immunotherapy for use in the treatment of a wide range of cancers. Heat Biologics CEO Jeffrey Wolf talks about the company’s ImPACT Therapy and two clinical trials.

To learn more about Heat Biologics visit:
www.heatbio.com

Star Wars fans and aspiring Jedi are going to want to see what Uncle Milton has in store this year, the company’s line of Star Wars Science toys previously brought us The Force Trainer which allowed fans to move objects using the power of their mind. The futuristic toy has received an update, using the same brain wave reader technology. The Force Trainer II: Hologram Experience harnesses the power of your mind to complete jedi challenges, so grab your light saber because ClearVISION/Corporate Profile Host Annamaria Stewart is going to show you how to unleash the force.

This episode is currently airing on ClearVISION, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers.

To learn more about the products featured in this episode visit:
WWW.UNCLEMILTON.COM

2015 should prove to be an exciting year for LEGO fans, as the company is debuting 313 new products; the largest collection of new building sets the company has ever released. Among the new themes are building sets from LEGO Elves, The Avengers, Jurassic World, Justice League, Star Wars, and Minecraft. If you are a fan of LEGO classics you can now purchase a set of bricks in the full LEGO color palette. You might have to wait to get your hands on these new LEGO building sets but you can let the excitement build as ClearVISION/CorporateProfile Host Annamaria Stewart gives you a sneak peak into the magical world LEGO has in store for you this year.

This episode is currently airing on ClearVISION, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers.

To learn more about the products featured in this episode visit:
WWW.LEGO.COM